References

Global epidemiology and future trends of heart failure

10.21037/amj.2020.03.03 · 2020 · External reference

Heart Failure with Reduced Ejection Fraction: A Review

External reference

Clinical Practice Guidelines: Management of Heart Failure (4th Edition 2019)

2019 · External reference

Demographic characteristics differences across EF subgroups in the Malaysian heart failure (MyHF) registry

External reference

Prognostic Factors in Hospitalization for Heart Failure in Asia

10.1016/j.hfc.2015.07.006 · 2015 · External reference

Heart failure across Asia: same healthcare burden but differences in organization of care

10.1016/j.ijcard.2016.07.256 · 2016 · External reference

Financial burden of heart failure in Malaysia: A perspective from the public healthcare system

2023 · External reference

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2021 · External reference

Sodium–glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction

External reference

Cardiovascular and renal outcomes with empagliflozin in heart failure

10.1056/nejmoa2022190 · 2020 · External reference

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

2022 · External reference

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients with Heart Failure by Baseline Diabetes Status: Results from the EMPEROR-Reduced Trial

10.1161/circulationaha.120.051824 · 2021 · External reference

MANAGEMENT OF HEART FAILURE 2023 5th Edition CLINICAL PRACTICE GUIDELINES

2023 · External reference

Budget Impact Analysis of Dapagliflozin in Treating Patients With Heart Failure With Reduced Ejection Fraction From the Perspective of Malaysian Public Healthcare System

2024 · External reference

POSC126 Budget Impact Analysis of Adopting Sodium-Glucose Cotransporter-2 Inhibitor for Treatment of Type 2 Diabetes Mellitus in Ministry of Health Malaysia

10.1016/j.jval.2021.11.530 · 2022 · External reference

Healthcare Resource Guide Malaysia

External reference

Budget impact analysis—Principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force

10.1016/j.jval.2013.08.2291 · 2014 · External reference

Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event

10.1007/s12325-021-01681-2 · 2021 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017

10.1093/eurjpc/zwaa147 · 2021 · External reference

Malaysian Heart Failure (MYHF) Registry substantiates high burden of comorbidities across the continuum of ejection fraction in Malaysian HF patients

10.1016/j.ijcard.2021.10.055 · 2021 · External reference

Unresolved reference

External reference

Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial

10.1016/j.jacc.2021.01.033 · 2021 · External reference

Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study

2022 · External reference

Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts

10.1007/s12325-016-0454-y · 2017 · External reference

Prevalence of chronic kidney disease and its associated factors in Malaysia; Findings from a nationwide population-based cross-sectional study

10.1186/s12882-020-01966-8 · 2020 · External reference

The Cost and Quality of Life of Malaysian Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease and Anemia

10.1016/j.vhri.2017.06.002 · 2018 · External reference

EE499 Budget Impact Analysis of Empagliflozin in Patients with Heart Failure in Sweden

10.1016/j.jval.2022.04.746 · 2022 · External reference

Economic Evaluation Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa

10.1016/j.vhri.2022.08.012 · 2023 · External reference

Cost-of-illness studies in heart failure: A systematic review 2004–2016

10.1186/s12872-018-0815-3 · External reference

PROGRAM PERKHIDMATAN FARMASI PHARMACEUTICAL SERVICES PROGRAMME

External reference

How well does Malaysia achieve value for money in public sector purchasing of medicines? Evidence from medicines procurement prices from 2010 to 2014

10.1186/s12913-020-05362-8 · 2020 · External reference

National Health and Morbidity Survey 2019 Technical Report Volume II: Healthcare Demand

2019 · External reference

“PDB9 Budget IMPACT Analysis of Empagliflozin in Type-2 Diabetes Patients with High Cardiovascular Risk in South Korea Based on Empa-REG OUTCOME® Trial: HIRA(HEALTH INSURANCE REVIEW & ASSESSMENT SERVICE)-NPS (NATIONAL PATIENTS SAMPLE) Database

10.1016/j.vhri.2020.07.168 · 2020 · External reference

Budget Impact Analysis of Empagliflozin For The Treatment of Patients With Type 2 Diabetes Mellitus At Increased Cardiovascular Risk In Greece

10.1016/j.jval.2017.08.440 · 2017 · External reference

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial

10.1111/dom.14535 · 2021 · External reference

Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations

10.1371/journal.pone.0110235 · 2014 · External reference

Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial

10.1111/dme.14076 · 2019 · External reference